protein

Apolipoprotein CIII, Human Plasma

MBS844044

0.1 mg

240 USD

Protein

Apolipoprotein CIII, Human Plasma

[Apolipoprotein CIII]

[Apolipoprotein CIII; apolipoprotein; apolipoproteins]

[apolipoprotein C-III; Apolipoprotein C-III; apolipoprotein C-III; apolipoprotein C-III; Apolipoprotein C3]

[APOC3]

[APOC3; APOC3; HALP2; APOCIII; Apo-CIII; ApoC-III]

APOC3_HUMAN

Human Plasma

99

>=95% by SDS-PAGE.

Frozen in 10 mM NH 4 HCO 3 , pH 7.4

Store at -70°C. Avoid multiple freeze/thaw cycles. Ships with blue ice.

SDS-PAGE; HPLC

Host Note: Human plasma. Shown to be non reactive for HBsAG, anti HCV, anti-HBc, and negative for anti-HIV 1&2 by FDA approved tests.

Proteins and Enzymes; ApolipoproteinsProteins and Enzymes; Native ProteinsProteins and Enzymes; Proteins and Enzymes (A-Z)

Background:. Apo CIII inhibits the activation of lipoprotein lipase by Apo CII. Reduced levels of Apo CIII result in higher fatty acid uptake from plasma triglycerides into adipose tissue. Thus, Apo CIII is a potential target for treatment of obesity and insulin resistance. The normal plasma concentration of Apo CIII is 8-15 mg per 100 ml.

4557323

NP_000031.1

NM_000040.1

P02656

8.750 kDa

Chylomicron-mediated Lipid Transport Pathway (1270006); HDL-mediated Lipid Transport Pathway (1270007); Lipid Digestion, Mobilization, And Transport Pathway (1270002); Lipoprotein Metabolism Pathway (1270005); Metabolism Pathway (1269956); Metabolism Of Lipids And Lipoproteins Pathway (1270001); PPAR Signaling Pathway (83042); PPAR Signaling Pathway (450); Retinoid Metabolism And Transport Pathway (1269624); Signal Transduction Pathway (1269379)

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq, Jul 2008]

APOC3: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. Defects in APOC3 are the cause of hyperalphalipoproteinemia type 2 (HALP2). HALP2 is a condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels. Belongs to the apolipoprotein C3 family. Protein type: Secreted, signal peptide; Secreted; Lipid-binding. Chromosomal Location of Human Ortholog: 11q23.3. Cellular Component: extracellular space; chylomicron; early endosome; extracellular region. Molecular Function: lipase inhibitor activity; cholesterol binding; phospholipid binding; enzyme regulator activity. Biological Process: response to drug; response to peptide hormone stimulus; cholesterol metabolic process; phototransduction, visible light; regulation of Cdc42 protein signal transduction; lipoprotein metabolic process; cholesterol efflux; G-protein coupled receptor protein signaling pathway; cholesterol homeostasis; reverse cholesterol transport; triacylglycerol metabolic process; phospholipid efflux; negative regulation of lipid catabolic process; lipoprotein transport; triacylglycerol catabolic process; negative regulation of lipoprotein lipase activity; negative regulation of receptor-mediated endocytosis; inflammatory response; triacylglycerol mobilization; negative regulation of lipid metabolic process; retinoid metabolic process; response to nutrient; negative regulation of fatty acid biosynthetic process. Disease: Apolipoprotein C-iii Deficiency

0.1 mg

240 USD